EVFM (Evofem Biosciences) Total Operating Expense: $19.03 Mil (TTM As of Mar. 2026)


What is Evofem Biosciences Total Operating Expense?

Evofem Biosciences EVFM -9.09% Total Operating Expense is $19.03 Mil as of Mar. 2026. The stock has 5 warning signs investors should review.

Evofem Biosciences's Total Operating Expense for the three months ended in Mar. 2026 was $5.06 Mil. Evofem Biosciences's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $19.03 Mil.

Evofem Biosciences Total Operating Expense Related Terms

Evofem Biosciences Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Total Operating Expense Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 170.99 96.55 29.55 23.21 14.13

Evofem Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 5.32 5.03 3.62 5.06

Evofem Biosciences Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $19.03 Mil mean?
Evofem Biosciences (EVFM) has a Total Operating Expense of $19.03 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Evofem Biosciences and its competitors.
Is Evofem Biosciences' Total Operating Expense too high?
Evofem Biosciences' current Total Operating Expense is $19.03 Mil.
How does Evofem Biosciences' Total Operating Expense compare to LYRA and CLSDQ?
Evofem Biosciences' Total Operating Expense of $19.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current Total Operating Expense is $19.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 20% below its estimated fair value. The current Total Operating Expense is $19.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Total Operating Expense is $19.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.